Asset
.ALPHA.1-PROTEINASE INHIBITOR HUMAN
Grifols S.A. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02282527 | phase2_3 | completed | 2014-10-01 | 2016-01-01 | Grifols Therapeutics LLC | A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency |
| NCT01213043 | phase2 | completed | 2010-11-01 | 2012-01-01 | Grifols Therapeutics LLC | Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency |
| NCT04495101 | phase2 | completed | 2020-07-29 | 2021-04-26 | Instituto Grifols, S.A. | Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19 |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 103174 | BLA | Grifols Therapeutics LLC |
Marketed products (5)
- prolastin,prolastin-c,prolastin-c liquid
- prolastin,prolastin-c,prolastin-c liquid
- prolastin,prolastin-c,prolastin-c liquid
- prolastin,prolastin-c,prolastin-c liquid
- prolastin,prolastin-c,prolastin-c liquid